https://doi.org/10.55788/ede71ed1
Cardiorespiratory fitness is associated with favourable health outcomes, but the impact on the risk of incident AD/ADRD is unknown [1]. This relationship was examined in 649,605 military veterans in the Veterans Health Administration database who completed a standardised exercise treadmill test between 2000 and 2017 and did not have ADRD at that time [2]. Participants were aged between 30 and 95 years (average age: 61 years); 5.7% were women and 16.6% African Americans. Based on peak metabolic equivalents (METs) during the first exercise treadmill test, they were differentiated into 5 age-specific fitness categories: lowest-fit (n=132,634; METs=3.8), low-fit (n=129,493; METs=5.8), moderate-fit (n=120,988; METs=7.5), fit (n=137,122; METs=9.2), and highest-fit (n=129,368, METs=11.7). The lowest-fit group was the reference to establishing hazard ratios for incident ADRD. The average follow-up was 8.8 years.
The results showed a strong, graded, inverse association between cardiorespiratory fitness and ADRD risk. Incident rates for ADRD were 9.5, 8.5, 7.4, 7.2 and 6.4 per 1,000 person-years in the low-fit, moderate-fit, high-fit, and highest-fit group, respectively (P<0.001). The adjusted HR for incident ADRD in respectively the lowest-fit to the highest-fit group were 0.87 (95% CI 0.85–0.90; P<0.001), 0.80 (95% CI 0.78–0.83; P<0.001), 0.74 (95% CI 0.72–0.76; P<0.001), and 0.67 (95% CI 0.65–0.70; P<0.001), respectively, compared with the lowest-fit group. A limitation of the study was that most participants were men and white.
“One exciting finding of this study is that as people’s fitness improved, their risk of AD decreased – it was not an all-or-nothing proposition,” said study author Dr Edward Zamrini (Washington DC VA Medical Center, DC, USA). “So people can work towards making incremental changes and improvements in their physical fitness, which will then hopefully be associated with a related decrease in their future risk of AD.”
- Rolland Y, et al. Clin Geriatr Med. 2010;26(1):75–87.
- Zamrini E, et al. Cardiorespiratory fitness is protective against Alzheimer’s and related disorders. S15.008, AAN 2022, 02–07 April, Seattle, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Safety and effects of bosutinib in Lewy body dementia Next Article
Targeting senescent cells to treat age-related diseases »
« Safety and effects of bosutinib in Lewy body dementia Next Article
Targeting senescent cells to treat age-related diseases »
Table of Contents: AAN 2022
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer’s Disease and Other Dementias
Targeting senescent cells to treat age-related diseases
Cardiorespiratory fitness protects against dementia
Safety and effects of bosutinib in Lewy body dementia
Epilepsy
“Women with epilepsy should be encouraged to breastfeed”
Fenfluramine: possible new treatment for Lennox-Gastaut syndrome
Laser interstitial thermal therapy for refractory epilepsy
Migraine
Migraine may be an important obstetric risk factor
Intranasal zavegepant safe and well tolerated in healthy adults
Telemedicine during COVID-19 pandemic highly appreciated
Multiple Sclerosis
Ublituximab versus teriflunomide in relapsing MS patients
Ketogenic diet may improve disability and quality of life
Favourable additional safety data for ofatumumab
Predicting new T2 lesions using a machine learning algorithm
Evobrutinib reduces volume of slowly expanding lesions
Sustained long-term efficacy and safety of satralizumab in NMOSD
Muscle and Neuro-Muscular Disorders
Ravulizumab in patients with generalised myasthenia gravis
Gene therapy effective in older patients with spinal muscular atrophy
Losmapimod for facioscapulohumeral muscular dystrophy
SRP-9001 for treating patients with Duchenne muscular dystrophy
Cerebrovascular Disease and Stroke
Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out?
Better outcomes with mechanical thrombectomy in elderly stroke patients
Plasma NfL levels associated with cardiovascular risk
Non-invasive vagus nerve stimulation for acute stroke
Parkinson’s Disease
Prasinezumab in Parkinson’s disease: delayed-start analysis of PASADENA trial
IPX203 versus immediate release carbidopa-levodopa
Impact of COVID-19 public health interventions
COVID-19
Cognitive, EEG, and MRI features in COVID-19 survivors
Neurological manifestations of COVID-19 worsen prognosis
New evidence for biological basis of “COVID-19 brain fog”
Related Articles
November 19, 2021
Adequate response to SARS-CoV-2 vaccine in cancer patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com